A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Summary

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.

The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected.

The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.

Conditions

• Advanced Thyroid Cancer Patients Who Received Target Therapy

Interventions

DRUG

dabrafenib plus trametinib with or without PD-1 antibody

advanced thyroid cancer patients who harbor BRAF V600E mutation

DRUG

entrectinib or larotrectinib with or without anti-PD-1 antibdoy

advanced thyroid cancer patients who harbor NTRK mutation

DRUG

pralsetinib or selpercatinib with or without anti-PD-1 antibdoy

advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

DRUG

anlotinib or anlotinib plus anti-PD-1 antibody

For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

DRUG

lenvatinib plus anti-PD-1 antibody

Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

DRUG

Other Targets: precise treatment based on the target

Advanced thyroid cancer patients who had other treatment targets not included above

Sponsors & Collaborators

• Peking Union Medical College Hospital

  collaborator OTHER

• Shanxi Province Cancer Hospital

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• The Affiliated Hospital of Inner Mongolia Medical University

  collaborator OTHER

• Ruijin Hospital

  collaborator OTHER

• Fujian Cancer Hospital

  collaborator OTHER_GOV

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• Shanghai 6th People's Hospital

  collaborator OTHER

• Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

  collaborator OTHER

• Shanghai 10th People's Hospital

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Changhai Hospital

  collaborator OTHER

• Tianjin Medical University Cancer Institute and Hospital

  collaborator OTHER

• Jiangsu Cancer Institute & Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui University of Chinese Medicine

  collaborator OTHER

• Hunan Provincial People's Hospital

  collaborator OTHER

• Dalian Friendship Hospital Affiliated to Dalian Medical University

  collaborator UNKNOWN

• The Third Affiliated Hospital of Soochow University

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Fudan University

  lead OTHER

Principal Investigators

• Dongmei Ji, M.D · Fudan University

• Yu Wang, M.D · Fudan University

• Qinghai Ji, M.D · Fudan University

• Yansong Lin, M.D · Peking Union Medical College Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-01-01

Primary Completion

2026-12-31

Completion

2028-12-31

Countries

• China

Study Locations